{"id":54101,"date":"2026-01-14T21:30:13","date_gmt":"2026-01-14T13:30:13","guid":{"rendered":"https:\/\/flcube.com\/?p=54101"},"modified":"2026-01-14T21:30:14","modified_gmt":"2026-01-14T13:30:14","slug":"immuneoncos-imm2510-advances-to-phase-ii-iii-in-endometrial-cancer-after-axion-bio-deal-termination","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=54101","title":{"rendered":"ImmuneOnco\u2019s IMM2510 Advances to Phase\u202fII\/III in Endometrial Cancer After Axion Bio Deal Termination"},"content":{"rendered":"\n<p><strong>ImmuneOnco Biopharmaceuticals (Shanghai) Co., Ltd.<\/strong> (<a href=\"https:\/\/www.google.com\/finance\/quote\/1541:HKG\">HKG:\u202f1541<\/a>) announced that China\u2019s <strong>National Medical Products Administration (NMPA)<\/strong> has approved a <strong>Phase\u202fII\/III study<\/strong> for <strong>IMM2510 (palverafusp \u03b1)<\/strong>, a <strong>PD\u2011L1\u00d7VEGF bispecific antibody<\/strong>, in <strong>primary advanced or recurrent endometrial cancer<\/strong> as monotherapy and in combination with chemotherapy. The company <strong>regained full global rights<\/strong> following the <strong>termination of its ex\u2011Greater China licensing agreement with Axion Bio, Inc.<\/strong> on 6\u202fJan\u202f2026.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-regulatory-milestone\">Regulatory Milestone<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Item<\/th><th>Detail<\/th><\/tr><\/thead><tbody><tr><td><strong>Company<\/strong><\/td><td>ImmuneOnco Biopharmaceuticals (HKEX:\u202f1541)<\/td><\/tr><tr><td><strong>Drug<\/strong><\/td><td>IMM2510 (palverafusp \u03b1)<\/td><\/tr><tr><td><strong>Application<\/strong><\/td><td>Phase\u202fII\/III Clinical Trial Approval<\/td><\/tr><tr><td><strong>Agency<\/strong><\/td><td>NMPA (China)<\/td><\/tr><tr><td><strong>Indication<\/strong><\/td><td>Primary advanced\/recurrent endometrial cancer (1L)<\/td><\/tr><tr><td><strong>Design<\/strong><\/td><td>Monotherapy and combination with chemotherapy<\/td><\/tr><tr><td><strong>Approval Date<\/strong><\/td><td>10\u202fJan\u202f2026<\/td><\/tr><tr><td><strong>Previous Indication<\/strong><\/td><td>NSCLC (Phase\u202fI\/II approved)<\/td><\/tr><tr><td><strong>Licensing Update<\/strong><\/td><td>Ex\u2011China rights from Axion Bio terminated; full rights regained<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-drug-profile-amp-mechanism-of-action\">Drug Profile &amp; Mechanism of Action<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Mechanism:<\/strong> IMM2510 is a <strong>PD\u2011L1\u00d7VEGF bispecific antibody (BsAb)<\/strong> that simultaneously <strong>blocks PD\u2011L1 immune checkpoint<\/strong> and <strong>inhibits VEGF\u2011driven angiogenesis<\/strong>, creating synergistic anti\u2011tumor activity<\/li>\n\n\n\n<li><strong>Differentiation:<\/strong> Dual targeting in a single molecule offers <strong>convenience<\/strong> vs. combination regimens and potential for <strong>enhanced efficacy<\/strong> with manageable safety<\/li>\n\n\n\n<li><strong>Clinical Rationale:<\/strong> Endometrial cancer frequently exhibits <strong>PD\u2011L1 expression<\/strong> and <strong>VEGF pathway activation<\/strong>; limited 1L options for advanced disease beyond chemo\u2011immunotherapy combos<\/li>\n\n\n\n<li><strong>Pipeline Status:<\/strong> NSCLC trials ongoing; <strong>full rights regained<\/strong> enable global development strategy<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-market-opportunity-amp-competitive-landscape\">Market Opportunity &amp; Competitive Landscape<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Parameter<\/th><th>China<\/th><th>Global<\/th><\/tr><\/thead><tbody><tr><td><strong>Endometrial Cancer Incidence (2026E)<\/strong><\/td><td>82,000<\/td><td>320,000<\/td><\/tr><tr><td><strong>Advanced\/Recurrent Cases<\/strong><\/td><td>19,000<\/td><td>75,000<\/td><\/tr><tr><td><strong>1L Treatment\u2011Eligible<\/strong><\/td><td>12,000<\/td><td>48,000<\/td><\/tr><tr><td><strong>Current Standard<\/strong><\/td><td>Carboplatin + paclitaxel \u00b1 pembrolizumab<\/td><td><\/td><\/tr><tr><td><strong>Market Gap<\/strong><\/td><td>No approved PD\u2011L1\u00d7VEGF bispecific<\/td><td><\/td><\/tr><tr><td><strong>Addressable Market (2030E)<\/strong><\/td><td>\u00a53.5\u202fbillion<\/td><td>$2.8\u202fbillion<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Competitors:<\/strong><\/li>\n\n\n\n<li><strong>Keytruda + Lenvima<\/strong> (Merck\/Eisai) \u2013 combo approved but requires two agents<\/li>\n\n\n\n<li><strong>Dostarlimab<\/strong> (GSK) \u2013 PD\u20111 monotherapy approved in 2L; limited 1L data<\/li>\n\n\n\n<li><strong>Ivonescimab<\/strong> (Summit\/Akeso) \u2013 PD\u20111\/VEGF bispecific in Phase\u202fIII for multiple tumors; not yet in endometrial cancer<\/li>\n\n\n\n<li><strong>Strategic Moat:<\/strong> IMM2510 is the <strong>first PD\u2011L1\u00d7VEGF bispecific<\/strong> entering Phase\u202fIII for endometrial cancer; <strong>full rights<\/strong> enable <strong>ex\u2011China licensing<\/strong> in <strong>2027<\/strong><\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-strategic-positioning-amp-next-steps\">Strategic Positioning &amp; Next Steps<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Trial Design:<\/strong> Phase\u202fII\/III will enroll <strong>~400 patients<\/strong> across 25 Chinese centers; primary endpoint: <strong>PFS by BICR<\/strong>; secondary: OS, ORR, safety<\/li>\n\n\n\n<li><strong>Global Development:<\/strong> ImmuneOnco plans <strong>ex\u2011China partnership<\/strong> discussions in <strong>H2\u202f2026<\/strong>; US IND filing targeted for <strong>2027<\/strong> leveraging China data<\/li>\n\n\n\n<li><strong>Manufacturing:<\/strong> Shanghai GMP facility (capacity 2,000\u202fL) already producing IMM2510 for NSCLC trials; scalable to 10,000\u202fL by <strong>Q4\u202f2026<\/strong><\/li>\n\n\n\n<li><strong>Financial Impact:<\/strong> Deal termination with Axion Bio removes royalty obligations; <strong>full revenue retention<\/strong> in key markets boosts valuation<\/li>\n<\/ul>\n\n\n\n<p><strong>Forward\u2011Looking Statements<\/strong><br>This brief contains forward\u2011looking statements regarding clinical trial timelines, regulatory pathways, and commercial strategies for IMM2510. Actual results may differ due to competitive dynamics, clinical outcomes, and partnership negotiations.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>ImmuneOnco Biopharmaceuticals (Shanghai) Co., Ltd. (HKG:\u202f1541) announced that China\u2019s National Medical Products Administration (NMPA) has&#8230;<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,11],"tags":[62,1028,229,28],"class_list":["post-54101","post","type-post","status-publish","format-standard","hentry","category-company","category-drug","tag-clinical-trial-approval-initiation","tag-hkg-1541","tag-immuneonco-biopharmaceuticals","tag-multi-specific-antibodies"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v23.6 (Yoast SEO v27.5) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>ImmuneOnco\u2019s IMM2510 Advances to Phase\u202fII\/III in Endometrial Cancer After Axion Bio Deal Termination - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"ImmuneOnco Biopharmaceuticals (Shanghai) Co., Ltd. (HKG:\u202f1541) announced that China\u2019s National Medical Products Administration (NMPA) has approved a Phase\u202fII\/III study for IMM2510 (palverafusp \u03b1), a PD\u2011L1\u00d7VEGF bispecific antibody, in primary advanced or recurrent endometrial cancer as monotherapy and in combination with chemotherapy. The company regained full global rights following the termination of its ex\u2011Greater China licensing agreement with Axion Bio, Inc. on 6\u202fJan\u202f2026.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=54101\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"ImmuneOnco\u2019s IMM2510 Advances to Phase\u202fII\/III in Endometrial Cancer After Axion Bio Deal Termination\" \/>\n<meta property=\"og:description\" content=\"ImmuneOnco Biopharmaceuticals (Shanghai) Co., Ltd. (HKG:\u202f1541) announced that China\u2019s National Medical Products Administration (NMPA) has approved a Phase\u202fII\/III study for IMM2510 (palverafusp \u03b1), a PD\u2011L1\u00d7VEGF bispecific antibody, in primary advanced or recurrent endometrial cancer as monotherapy and in combination with chemotherapy. The company regained full global rights following the termination of its ex\u2011Greater China licensing agreement with Axion Bio, Inc. on 6\u202fJan\u202f2026.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=54101\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-01-14T13:30:13+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-01-14T13:30:14+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1894\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=54101#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=54101\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"ImmuneOnco\u2019s IMM2510 Advances to Phase\u202fII\\\/III in Endometrial Cancer After Axion Bio Deal Termination\",\"datePublished\":\"2026-01-14T13:30:13+00:00\",\"dateModified\":\"2026-01-14T13:30:14+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=54101\"},\"wordCount\":439,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"keywords\":[\"Clinical trial approval \\\/ initiation\",\"HKG: 1541\",\"ImmuneOnco Biopharmaceuticals\",\"Multi-specific antibodies\"],\"articleSection\":[\"Company\",\"Drug\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=54101#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=54101\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=54101\",\"name\":\"ImmuneOnco\u2019s IMM2510 Advances to Phase\u202fII\\\/III in Endometrial Cancer After Axion Bio Deal Termination - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"datePublished\":\"2026-01-14T13:30:13+00:00\",\"dateModified\":\"2026-01-14T13:30:14+00:00\",\"description\":\"ImmuneOnco Biopharmaceuticals (Shanghai) Co., Ltd. (HKG:\u202f1541) announced that China\u2019s National Medical Products Administration (NMPA) has approved a Phase\u202fII\\\/III study for IMM2510 (palverafusp \u03b1), a PD\u2011L1\u00d7VEGF bispecific antibody, in primary advanced or recurrent endometrial cancer as monotherapy and in combination with chemotherapy. The company regained full global rights following the termination of its ex\u2011Greater China licensing agreement with Axion Bio, Inc. on 6\u202fJan\u202f2026.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=54101#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=54101\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=54101#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"ImmuneOnco\u2019s IMM2510 Advances to Phase\u202fII\\\/III in Endometrial Cancer After Axion Bio Deal Termination\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"ImmuneOnco\u2019s IMM2510 Advances to Phase\u202fII\/III in Endometrial Cancer After Axion Bio Deal Termination - Insight, China&#039;s Pharmaceutical Industry","description":"ImmuneOnco Biopharmaceuticals (Shanghai) Co., Ltd. (HKG:\u202f1541) announced that China\u2019s National Medical Products Administration (NMPA) has approved a Phase\u202fII\/III study for IMM2510 (palverafusp \u03b1), a PD\u2011L1\u00d7VEGF bispecific antibody, in primary advanced or recurrent endometrial cancer as monotherapy and in combination with chemotherapy. The company regained full global rights following the termination of its ex\u2011Greater China licensing agreement with Axion Bio, Inc. on 6\u202fJan\u202f2026.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=54101","og_locale":"en_US","og_type":"article","og_title":"ImmuneOnco\u2019s IMM2510 Advances to Phase\u202fII\/III in Endometrial Cancer After Axion Bio Deal Termination","og_description":"ImmuneOnco Biopharmaceuticals (Shanghai) Co., Ltd. (HKG:\u202f1541) announced that China\u2019s National Medical Products Administration (NMPA) has approved a Phase\u202fII\/III study for IMM2510 (palverafusp \u03b1), a PD\u2011L1\u00d7VEGF bispecific antibody, in primary advanced or recurrent endometrial cancer as monotherapy and in combination with chemotherapy. The company regained full global rights following the termination of its ex\u2011Greater China licensing agreement with Axion Bio, Inc. on 6\u202fJan\u202f2026.","og_url":"https:\/\/flcube.com\/?p=54101","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-01-14T13:30:13+00:00","article_modified_time":"2026-01-14T13:30:14+00:00","og_image":[{"width":2560,"height":1894,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","type":"image\/jpeg"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=54101#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=54101"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"ImmuneOnco\u2019s IMM2510 Advances to Phase\u202fII\/III in Endometrial Cancer After Axion Bio Deal Termination","datePublished":"2026-01-14T13:30:13+00:00","dateModified":"2026-01-14T13:30:14+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=54101"},"wordCount":439,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"keywords":["Clinical trial approval \/ initiation","HKG: 1541","ImmuneOnco Biopharmaceuticals","Multi-specific antibodies"],"articleSection":["Company","Drug"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=54101#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=54101","url":"https:\/\/flcube.com\/?p=54101","name":"ImmuneOnco\u2019s IMM2510 Advances to Phase\u202fII\/III in Endometrial Cancer After Axion Bio Deal Termination - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"datePublished":"2026-01-14T13:30:13+00:00","dateModified":"2026-01-14T13:30:14+00:00","description":"ImmuneOnco Biopharmaceuticals (Shanghai) Co., Ltd. (HKG:\u202f1541) announced that China\u2019s National Medical Products Administration (NMPA) has approved a Phase\u202fII\/III study for IMM2510 (palverafusp \u03b1), a PD\u2011L1\u00d7VEGF bispecific antibody, in primary advanced or recurrent endometrial cancer as monotherapy and in combination with chemotherapy. The company regained full global rights following the termination of its ex\u2011Greater China licensing agreement with Axion Bio, Inc. on 6\u202fJan\u202f2026.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=54101#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=54101"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=54101#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"ImmuneOnco\u2019s IMM2510 Advances to Phase\u202fII\/III in Endometrial Cancer After Axion Bio Deal Termination"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/54101","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=54101"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/54101\/revisions"}],"predecessor-version":[{"id":54102,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/54101\/revisions\/54102"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=54101"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=54101"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=54101"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}